Vascular Endothelial Growth Factor (VEGF) Prevents the Downregulation of the Cholinergic Phenotype in Axotomized Motoneurons of the Adult Rat

被引:10
|
作者
Acosta, Lourdes [1 ]
Morcuende, Sara [1 ]
Silva-Hucha, Silvia [1 ]
Pastor, Angel M. [1 ]
de la Cruz, Rosa R. [1 ]
机构
[1] Univ Seville, Fac Biol, Dept Fisiol, Seville, Spain
来源
关键词
VEGF; axotomy; oculomotor system; amyotrophic lateral sclerosis; angiogenesis; laminin; glucose transporter 1 (GLUT-1); acetylcholine; AMYOTROPHIC-LATERAL-SCLEROSIS; CENTRAL-NERVOUS-SYSTEM; SPINAL MOTOR-NEURONS; LONG-TERM SURVIVAL; NEUROTROPHIC FACTOR; IN-VIVO; EXTRAOCULAR MOTONEURONS; POSTNATAL-DEVELOPMENT; PROLONGS SURVIVAL; GENE-EXPRESSION;
D O I
10.3389/fnmol.2018.00241
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Vascular endothelial growth factor (VEGF) was initially characterized by its activity on the vascular system. However, there is growing evidence indicating that VEGF also acts as a neuroprotective factor, and that its administration to neurons suffering from trauma or disease is able to rescue them from cell death. We questioned whether VEGF could also maintain damaged neurons in a neurotransmissive mode by evaluating the synthesis of their neurotransmitter, and whether its action would be direct or through its well-known angiogenic activity. Adult rat extraocular motoneurons were chosen as the experimental model. Lesion was performed by monocular enucleation and immediately a gelatine sponge soaked in VEGF was implanted intraorbitally. After 7 days, abducens, trochlear, and oculomotor nuclei were examined by immunohistochemistry against choline acetyltransferase (ChAT), the biosynthetic enzyme of the motoneuronal neurotransmitter acetylcholine. Lesioned motoneurons exhibited a noticeable ChAT downregulation which was prevented by VEGF administration. To explore whether this action was mediated via an increase in blood vessels or in their permeability, we performed immunohistochemistry against laminin, glucose transporter-1 and the plasmatic protein albumin. The quantification of the immunolabeling intensity against these three proteins showed no significant differences between VEGF-treated, axotomized and control animals. Therefore, the present data indicate that VEGF is able to sustain the cholinergic phenotype in damaged motoneurons, which is a first step for adequate neuromuscular neurotransmission, and that this action seems to be mediated directly on neurons since no sign of angiogenic activity was evident. These data reinforces the therapeutical potential of VEGF in motoneuronal diseases.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Glycine prevents apoptosis of sinusoidal endothelial cells due to vascular endothelial growth factor (VEGF) deprivation.
    Zhang, YJ
    Ikejima, K
    Takei, Y
    Honda, H
    Hirose, M
    Fukuda, T
    Kitamura, T
    Oide, H
    Miyazaki, A
    Watanabe, S
    Sato, N
    HEPATOLOGY, 1999, 30 (04) : 225A - 225A
  • [22] Extraocular motoneurons of the adult rat show higher levels of vascular endothelial growth factor and its receptor Flk-1 than other cranial motoneurons
    Silva-Hucha, Silvia
    Hernandez, Rosendo G.
    Benitez-Temino, Beatriz
    Pastor, Angel M.
    de la Cruz, Rosa R.
    Morcuende, Sara
    PLOS ONE, 2017, 12 (06):
  • [23] Vascular endothelial growth factor (VEGF) expression and the effect of exogenous VEGF on survival of a random flap in the rat
    Roman, S
    Poole, M
    Lindeman, R
    BRITISH JOURNAL OF PLASTIC SURGERY, 2004, 57 (02): : 174 - 174
  • [24] Vascular endothelial growth factor (VEGF) expression and the effect of exogenous VEGF on survival of a random flap in the rat
    Zhang, F
    Oswald, T
    Lin, S
    Cai, Z
    Lei, M
    Jones, M
    Angel, MF
    Lineaweaver, WC
    BRITISH JOURNAL OF PLASTIC SURGERY, 2003, 56 (07): : 653 - 659
  • [25] Vascular endothelial growth factor vascular permeability factor (VEGF) in diabetic retinopathy
    Kunz, M
    Merges, C
    McLeod, DS
    Lutty, GA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1996, 37 (03) : 571 - 571
  • [26] Cyclosporine toxicity and vascular endothelial growth factor (VEGF).
    Kubisz, Peter
    Grandtnerova, Barbara
    Laca, Ludovit
    Stasko, Jan
    BLOOD, 2006, 108 (11) : 58B - 58B
  • [27] Vascular endothelial growth factor (VEGF) expression in plasmacytoma
    Paydas, S
    Zorludemir, S
    Baslamisli, F
    Tuncer, I
    LEUKEMIA & LYMPHOMA, 2002, 43 (01) : 139 - 143
  • [28] Vascular Endothelial Growth Factor (VEGF) in Autoimmune Diseases
    JozÉlio Freire Carvalho
    Miri Blank
    Yehuda Shoenfeld
    Journal of Clinical Immunology, 2007, 27 : 246 - 256
  • [29] Vascular endothelial growth factor (VEGF) in autoimmune diseases
    Freire Carvalho, Jozelio
    Blank, Miri
    Shoenfeld, Yehuda
    JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (03) : 246 - 256
  • [30] Vascular endothelial growth factor (VEGF) and its receptors
    Neufeld, G
    Cohen, T
    Gengrinovitch, S
    Poltorak, Z
    FASEB JOURNAL, 1999, 13 (01): : 9 - 22